02575.HK
Xuanzhubio-b
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 8.60
+0.64%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4085.9%
- EBITDA
- +61.1%
- EBIT
- +58.6%
- Net income
- +55.9%
- EPS
- +56.0%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026